210 related articles for article (PubMed ID: 31307777)
1. HLA-DQ alloantibodies directly activate the endothelium and compromise differentiation of FoxP3
Cross AR; Lion J; Poussin K; Assayag M; Taupin JL; Glotz D; Mooney N
Kidney Int; 2019 Sep; 96(3):689-698. PubMed ID: 31307777
[TBL] [Abstract][Full Text] [Related]
2. Inflammation Determines the Capacity of Allogenic Endothelial Cells to Regulate Human Treg Expansion.
Cross AR; Lion J; Poussin K; Glotz D; Mooney N
Front Immunol; 2021; 12():666531. PubMed ID: 34305898
[TBL] [Abstract][Full Text] [Related]
3. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.
Lee H; Min JW; Kim JI; Moon IS; Park KH; Yang CW; Chung BH; Oh EJ
Medicine (Baltimore); 2016 Mar; 95(11):e3094. PubMed ID: 26986147
[TBL] [Abstract][Full Text] [Related]
5. Anti-human leukocyte antigen DQ antibodies in renal transplantation: Are we underestimating the most frequent donor specific alloantibodies?
Carta P; Di Maria L; Caroti L; Buti E; Antognoli G; Minetti EE
Transplant Rev (Orlando); 2015 Jul; 29(3):135-8. PubMed ID: 25976621
[TBL] [Abstract][Full Text] [Related]
6. Donor Specific Antibodies are not only directed against HLA-DR: Minding your Ps and Qs.
Cross AR; Lion J; Loiseau P; Charron D; Taupin JL; Glotz D; Mooney N
Hum Immunol; 2016 Nov; 77(11):1092-1100. PubMed ID: 27060781
[TBL] [Abstract][Full Text] [Related]
7. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation.
DeVos JM; Gaber AO; Knight RJ; Land GA; Suki WN; Gaber LW; Patel SJ
Kidney Int; 2012 Sep; 82(5):598-604. PubMed ID: 22622504
[TBL] [Abstract][Full Text] [Related]
8. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
[TBL] [Abstract][Full Text] [Related]
9. HLA Class II Antibody Activation of Endothelial Cells Promotes Th17 and Disrupts Regulatory T Lymphocyte Expansion.
Lion J; Taflin C; Cross AR; Robledo-Sarmiento M; Mariotto E; Savenay A; Carmagnat M; Suberbielle C; Charron D; Haziot A; Glotz D; Mooney N
Am J Transplant; 2016 May; 16(5):1408-20. PubMed ID: 26614587
[TBL] [Abstract][Full Text] [Related]
10. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy.
Willicombe M; Brookes P; Sergeant R; Santos-Nunez E; Steggar C; Galliford J; McLean A; Cook TH; Cairns T; Roufosse C; Taube D
Transplantation; 2012 Jul; 94(2):172-7. PubMed ID: 22735711
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Mediated Rejection Due to Donor-Specific HLA-DQB1 and DQA1 Antibodies After Kidney Transplantation: A Case Report.
Thammanichanond D; Tammakorn C; Worawichawong S; Kantachuvesiri S
Transplant Proc; 2020; 52(6):1931-1936. PubMed ID: 32444122
[TBL] [Abstract][Full Text] [Related]
12. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
[TBL] [Abstract][Full Text] [Related]
13. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after heart transplantation.
Omrani O; Alawwami M; Buraiki J; Selimovic N
Ann Saudi Med; 2018; 38(2):97-104. PubMed ID: 29620542
[TBL] [Abstract][Full Text] [Related]
14. Effects of alloantibodies to human leukocyte antigen on endothelial expression and serum levels of thrombomodulin.
Béland S; Vallin P; Désy O; Lévesque E; De Serres SA
J Thromb Haemost; 2017 May; 15(5):1020-1031. PubMed ID: 28239987
[TBL] [Abstract][Full Text] [Related]
15. Donor-specific antibodies present at the time of kidney transplantation in immunologically unmodified patients increase the risk of acute rejection.
Gupta A; Murillo D; Yarlagadda SG; Wang CJ; Nawabi A; Schmitt T; Brimacombe M; Bryan CF
Transpl Immunol; 2016 Jul; 37():18-22. PubMed ID: 27137749
[TBL] [Abstract][Full Text] [Related]
16. Markers of graft microvascular endothelial injury may identify harmful donor-specific anti-HLA antibodies and predict kidney allograft loss.
Louis K; Hertig A; Taupin JL; Buob D; Jamme M; Brocheriou I; Luque Y; Jouanneau C; Ouali N; Audouin M; Rondeau E; Xu-Dubois YC
Am J Transplant; 2019 Sep; 19(9):2434-2445. PubMed ID: 30836425
[TBL] [Abstract][Full Text] [Related]
17. Donor-specific antibody to trans-encoded donor HLA-DQ heterodimer.
Habig DF; Gaspari JL; Lokhandwala PM; Domen RE; Abendroth CS; Kadry Z; Ghahramani N; Shah RA; Jain A; Shike H
Hum Immunol; 2015 Aug; 76(8):587-90. PubMed ID: 26382246
[TBL] [Abstract][Full Text] [Related]
18. Unravelling the connections between donor specific antibodies and renal allograft pathology.
Chapman JR; Wavamunno M; O'Connell PJ; Nankivell BJ
Clin Transpl; 2013; ():361-5. PubMed ID: 25095530
[TBL] [Abstract][Full Text] [Related]
19. Epitope analysis of HLA-DQ antigens: what does the antibody see?
Tambur AR; Rosati J; Roitberg S; Glotz D; Friedewald JJ; Leventhal JR
Transplantation; 2014 Jul; 98(2):157-66. PubMed ID: 25003284
[TBL] [Abstract][Full Text] [Related]
20. The suppressive effect on CD4 T cell alloresponse against endothelial HLA-DR via PD-L1 induced by anti-A/B ligation.
Iwasaki K; Hamana H; Kishi H; Yamamoto T; Hiramitsu T; Okad M; Tomosugi T; Takeda A; Narumi S; Watarai Y; Miwa Y; Okumura M; Matsuoka Y; Horimi K; Muraguchi A; Kobayash T
Clin Exp Immunol; 2020 Nov; 202(2):249-261. PubMed ID: 32578199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
